Close Menu

NEW YORK (GenomeWeb) – Lucence Diagnostics and Singapore's Quest Laboratories have announced a new partnership under which Quest will offer blood tests developed by Lucence for cancer detection and treatment guidance to its customers in the region.

The blood tests will be based on Lucence's proprietary liquid biopsy technology. The company says it has developed assays for cancers common in Asia, like lung and colon cancer. The same tests can also read out germline cancer predisposition mutations like BRCA1 and BRCA2.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.